Genetics and pharmacogenetics in heart failure

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Heart failure is a heterogeneous disease, the development and pathophysiology of which involves complex interactions between genetic and environmental factors. It is well known that there are several heritable forms of heart failure in which genetic variation makes an individual more likely to develop the disease; however, less is clear about the degree to which genetics plays a role in the pathogenesis of more classic forms of heart failure. Several studies have been performed in patients with heart failure to determine the influence of modifier genes on exercise capacity, cardiovascular and pulmonary function, and outcomes, including survival. Given the variability in the response to pharmacologic treatment in patients with heart failure, there is an emerging interest in the optimal pharmacologic intervention for a given genotype in patients with heart failure. This review focuses primarily on several modifier genes, principally those associated with regulation of the adrenergic and rennin-angiotensin-aldosterone systems and those important to vascular control in heart failure, as well as the impact of these genes in the response to treatment.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalCurrent Heart Failure Reports
Volume4
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Pharmacogenetics
Heart Failure
Modifier Genes
Chymosin
Angiotensins
Genetics
Aldosterone
Adrenergic Agents
Blood Vessels
Genes
Genotype
Exercise
Lung
Survival
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Genetics and pharmacogenetics in heart failure. / Snyder, Eric M.; Olson, Thomas P; Johnson, Bruce David.

In: Current Heart Failure Reports, Vol. 4, No. 3, 09.2007, p. 139-144.

Research output: Contribution to journalArticle

@article{ff5861ca7ed54a198b664b1b95adf221,
title = "Genetics and pharmacogenetics in heart failure",
abstract = "Heart failure is a heterogeneous disease, the development and pathophysiology of which involves complex interactions between genetic and environmental factors. It is well known that there are several heritable forms of heart failure in which genetic variation makes an individual more likely to develop the disease; however, less is clear about the degree to which genetics plays a role in the pathogenesis of more classic forms of heart failure. Several studies have been performed in patients with heart failure to determine the influence of modifier genes on exercise capacity, cardiovascular and pulmonary function, and outcomes, including survival. Given the variability in the response to pharmacologic treatment in patients with heart failure, there is an emerging interest in the optimal pharmacologic intervention for a given genotype in patients with heart failure. This review focuses primarily on several modifier genes, principally those associated with regulation of the adrenergic and rennin-angiotensin-aldosterone systems and those important to vascular control in heart failure, as well as the impact of these genes in the response to treatment.",
author = "Snyder, {Eric M.} and Olson, {Thomas P} and Johnson, {Bruce David}",
year = "2007",
month = "9",
doi = "10.1007/s11897-007-0032-3",
language = "English (US)",
volume = "4",
pages = "139--144",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Genetics and pharmacogenetics in heart failure

AU - Snyder, Eric M.

AU - Olson, Thomas P

AU - Johnson, Bruce David

PY - 2007/9

Y1 - 2007/9

N2 - Heart failure is a heterogeneous disease, the development and pathophysiology of which involves complex interactions between genetic and environmental factors. It is well known that there are several heritable forms of heart failure in which genetic variation makes an individual more likely to develop the disease; however, less is clear about the degree to which genetics plays a role in the pathogenesis of more classic forms of heart failure. Several studies have been performed in patients with heart failure to determine the influence of modifier genes on exercise capacity, cardiovascular and pulmonary function, and outcomes, including survival. Given the variability in the response to pharmacologic treatment in patients with heart failure, there is an emerging interest in the optimal pharmacologic intervention for a given genotype in patients with heart failure. This review focuses primarily on several modifier genes, principally those associated with regulation of the adrenergic and rennin-angiotensin-aldosterone systems and those important to vascular control in heart failure, as well as the impact of these genes in the response to treatment.

AB - Heart failure is a heterogeneous disease, the development and pathophysiology of which involves complex interactions between genetic and environmental factors. It is well known that there are several heritable forms of heart failure in which genetic variation makes an individual more likely to develop the disease; however, less is clear about the degree to which genetics plays a role in the pathogenesis of more classic forms of heart failure. Several studies have been performed in patients with heart failure to determine the influence of modifier genes on exercise capacity, cardiovascular and pulmonary function, and outcomes, including survival. Given the variability in the response to pharmacologic treatment in patients with heart failure, there is an emerging interest in the optimal pharmacologic intervention for a given genotype in patients with heart failure. This review focuses primarily on several modifier genes, principally those associated with regulation of the adrenergic and rennin-angiotensin-aldosterone systems and those important to vascular control in heart failure, as well as the impact of these genes in the response to treatment.

UR - http://www.scopus.com/inward/record.url?scp=34848818792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848818792&partnerID=8YFLogxK

U2 - 10.1007/s11897-007-0032-3

DO - 10.1007/s11897-007-0032-3

M3 - Article

C2 - 17883989

AN - SCOPUS:34848818792

VL - 4

SP - 139

EP - 144

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 3

ER -